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5%–10% and o s  in the range of 2%–5%. However, 
the data are robust, given that the results of a meta-
analysis also demonstrated statistically significant 
benefits for interferon-treated as compared with 
untreated patients 3.
Why Did These Study Results Not Lead to a Global 
Consensus About Interferon Treatment  
as a Standard of Care?
First, apart from a single clinical trial reported by 
Kirkwood et al., which compared patients receiving 
h d i  2b with untreated controls [Eastern Cooperative 
Oncology Group (e c o g ) 1684], no other clinical 
trial has demonstrated a clear statistically significant 
benefit in o s  4. The question therefore arises whether 
a benefit in r f s  is also a clinically meaningful end-
point. The quality-of-life-adjusted survival analysis 
for patients treated with h d i  2b in the United States 
revealed that patients are willing to accept significant 
toxicity for even a modest improvement of r f s  in the 
absence of o s  benefit 5. In the absence of good treat-
ment alternatives apart from a “wait and see” policy, 
many German patients have also been willing to ac-
cept moderate-to-severe toxicity for minimal benefit 
when they are appropriately informed before treat-
ment initiation. However, more attention should be 
paid to this clinically important question that affects 
the quality of life of melanoma patients so much.
Second, as already mentioned, the toxicity of the 
approved h d i  2b is significant but manageable 6. Over 
the years of experience with this new drug regimen 
(approved in 1996 in the United States and Canada, 
and also later in Europe), the number of patients 
with toxicity-related treatment discontinuations has 
dropped significantly. In centres with many treated pa-
tients, the rate of treatment cessation is consistently in 
a range of 10% when established rules for a two-step 
interferon dose reduction scheme are respected 4,6. 
The h d i  scheme has already been implemented into 
national guidelines for the treatment of stage iii mela-
noma patients 7,8; however, because of dose-limiting 
toxicity and, most likely, also because of the high cost 
of this treatment, h d i  is outside the routine spectrum of 
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Malignant melanoma of the skin is the most frequent 
cause of mortality in skin cancer. Despite various 
efforts toward increased early detection and preven-
tion of melanoma, approximately 20% of patients 
will die because of disseminated metastases. Once 
melanoma has spread to regional lymph nodes, 
survival diminishes to approximately 30%–55% 
depending on micro- or macrometastases and the 
number of involved nodes. It is well established 
that the tumour load within the lymph node or nodes 
is an important predictor for disease-free survival 
(d f s ) and overall survival (o s ). Median survival for 
stage iv melanoma patients ranges from 6 months 
to 12 months, and to date, fewer than 10% of all 
stage iv patients demonstrate long-term survival. 
The poor outcome for patients with advanced 
metastatic melanoma indicates an urgent need for 
effective adjuvant treatment modalities for patients 
with high-risk disease.
Since the 1970s, dozens of prospective random-
ized controlled clinical trials for intermediate- and 
high-risk melanoma patients have been performed. 
In contrast to the situation with other solid malignan-
cies such as breast and colorectal cancer, no global 
consensus has been reached on an effective adjuvant 
treatment for melanoma patients 1.
Approaches using unspecific immunostimulation 
(bacille Calmette–Guérin, among others), interferon γ, 
conventional chemotherapy, and vaccination have not 
been demonstrated to improve d f s  or particularly o s  
in comparison with untreated controls 2.
Therefore, even in the year 2009, interferon alfa 
is the only agent being used in adjuvant treatment 
for melanoma that has showed at least a positive 
effect on relapse-free survival (r f s )—and in the 
case of high-dose interferon alfa (h d i ), also a posi-
tive effect on o s . However, those benefits provide 
only a modest improvement of r f s in the range of HAUSCHILD
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adjuvant treatment modalities in some countries such 
as the Netherlands and the United Kingdom.
In Europe, the question of the optimal dose of 
interferon alfa is even more critical, because not 
only h d i , but also low-dose interferon alfa (l d i) 
2a has been approved for the adjuvant treatment 
of melanoma. Interferon alfa 2a is approved for 
clinically lymph node–negative melanoma patients 
with a tumour thickness of at least 1.5 mm, which 
illustrates that not only patients who were sentinel 
node–negative, but also those who, before the in-
troduction of sentinel lymph node dissection, were 
sentinel node–positive, have been treated. In the 
French multicentre melanoma trial conducted by 
Grob et al., 499 stage ii melanoma patients with 
no clinical evidence of lymph node involvement 
received 3×106 IU thrice weekly for 18 months 9. 
Because of the moderate toxicity and lower costs as 
compared with h d i , l d i  became a standard of care in 
many European countries (that is, Germany, Aus-
tria, Switzerland, France). However, in countries 
such as the Netherlands and the United Kingdom, 
neither the positive effect of l d i  on d f s , nor its fa-
vourable toxicity profile has convinced physicians 
to use this scheme.
An illustrative example of the complex situ-
ation that results comes from my own melanoma 
centre in Kiel, Germany. Danish melanoma pa-
tients who want to receive adjuvant interferon 
outside of a clinical trial are treated there because 
interferon is not a standard of care in Denmark. 
“Melanoma tourism” to neighbouring centres in 
Germany is a logical consequence of that policy. To 
sum up, neither in Europe nor in the United States 
or Canada has a consensus been reached on the 
best treatment schedule or even use of interferon 
alfa at all 10.
In a large recently published clinical trial 
conducted by Eggermont et al. 11 for the European 
Organization for the Research and Treatment of 
Cancer (e o r t c) Melanoma Group, patients receiving 
pegylated interferon alfa 2b showed improved r f s 
for fully resected stage iii melanoma with micro- 
or macrometastases. The trial compared patients 
treated using pegylated interferon alfa 2b with un-
treated controls. The difference in r f s in absolute 
terms was 7% between the interferon-treated and 
the untreated patients. Sondak and Flaherty asked 
whether “this is the drug ... we were waiting for” in 
an editorial published in The Lancet 12. They brought 
forward a very important point, arguing that the 
strongest interferon benefit was observed in the 
subset of melanoma patients with micrometastases 
in the sentinel node. Not only was an improvement 
in r f s evident for this patient population, but also 
in distant metastases-free survival (d m f s). A less 
favourable outcome for patients receiving pegy-
lated interferon alfa 2b as compared with untreated 
controls was observed in the N2 patient population 
with clinically detectable macrometastases of the 
lymph nodes.
Is There Any Evidence That Interferon-Treated 
Patients May Benefit More If They Have Micro- as 
Compared with Macrometastases of the Lymph 
Nodes?
I believe that there is enough evidence to support the 
hypothesis that interferon-treated patients may benefit 
more if they have micrometastases than if they have 
macrometastases of the lymph nodes. In two clinical 
trials on a total of more than 2500 patients (e o r t c 18952 
and e o r t c 18991) published in recent years, a clear de-
pendency of interferon responsiveness on tumour load 
(stage iib/c > iiia > iiib) was observed 11,13. However, the 
biology behind those observations is currently unclear.
Furthermore, for the second time, melanoma 
patients with an ulcerated primary tumour treated 
with either conventional interferon alfa 2b or pegy-
lated interferon alfa 2b were demonstrated to respond 
better to interferons than did patients with a non-
ulcerated melanoma primary 11. This phenomenon 
has not been well understood biologically till now. In 
addition, some support for these findings comes from 
the Wheatley et al. 3 meta-analysis. Hence, ulceration 
of the primary tumour appears to be a predictive 
biologic parameter for responsiveness to interferon 
in the absence of any other validated molecular or 
immunologic markers for interferon response. The 
interesting observation of a correlation between the 
development of autoimmunity during interferon 
treatment and a better treatment outcome was con-
sistently shown in two reports 14,15. In an e o r t c  study, 
however, those results could not be confirmed when 
only a seroconversion of auto-antibodies during 
treatment was considered to be an autoimmune event. 
In any case, autoimmunity is clearly not a predictive 
marker before treatment initiation, but more a sur-
rogate marker of response.
The e o r t c  Melanoma Group will soon initiate a 
prospective randomized phase iii trial on sentinel 
node–negative patients with an ulcerated primary 
melanoma of more than 1.0 mm tumour thickness. 
Pegylated interferon alfa 2b will be compared with 
observation alone in approximately 1000 melanoma 
patients. That study, as well as previous clinical tri-
als, contains a translational research portion that 
will consider several potential biomarkers for inter-
feron responsiveness.
Have Any New Trial Results Emerged That May 
Contribute to Current Knowledge on the Adjuvant 
Treatment of Melanoma with Interferon?
In the January issue of the Journal of Clinical Oncology, 
Pectasides and coworkers from the Hellenic Coop-
erative Oncology Group published the results of a 
prospective randomized study on 4-week intravenous ADJUVANT INTERFERON ALFA FOR MELANOMA
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induction therapy with interferon alfa 2b as compared 
with a full year of a modified h d i  2b 16. A total of 364 
patients were enrolled, of whom 353 were evaluable 
for the study endpoints. Approximately 30% of the 
treated patients were stage iib/c, and roughly 60%were 
stage iiia/b/c, with most being stage iiib. In 11% of 
the patients in both treatment arms, the appropriate 
staging category was not known 16.
Compared with the original report and current 
treatment recommendations on h d i , the Greek patients 
received a dose of only 15×106 IU/m2 daily during the 
induction phase. This was a 25% reduction as compared 
with the doses used by Kirkwood et al. The mainte-
nance dose was also modified from the approved dose 
(10×106 IU/m2 thrice weekly, considered a 50% dose 
reduction) for “patients’ convenience of dosing and ad-
ministration.” The statistical analysis was confined to the 
primary endpoint of r f s  and secondary endpoints such 
as d m f s  and o s  in the intent-to-treat population.
The authors said that the study design was based 
on the hypothesis that the 1-month induction regi-
men (arm A) would be considered as efficacious as 
the conventional regimen (arm B) if the relapse rate 
at 3 years from study entry were to be no more than 
15% higher in arm A than in arm B. A sample size of 
308 patients was required to achieve a power of 85% 
in a one-sided test at a significance level of 0.05. The 
target accrual was set at 342 patients (171 patients per 
arm), anticipating a 10% withdrawal rate. Only a few 
patients (3 in arm A and 10 in arm B) discontinued 
the study treatment because of toxicity. A dose reduc-
tion was required in 25% of all patients during the 
intravenous treatment phase and in 9.6% of arm B 
patients during the subcutaneous maintenance phase. 
No unexpected toxicities or treatment-related deaths 
occurred. At a median follow-up of 63 months, no 
differences in r f s , d m f s , or o s  have been observed 
between the two treatment arms 16.
Is This Clinical Trial Changing the Current 
Treatment Recommendations for Patients with  
High Risk of Melanoma Relapse?
I have some doubts about the conclusion by Pecta-
sides et al. 16 that 1 month of h d i  2b has the same 
clinical benefit as 1 year of h d i . The following pitfalls 
can be critically discussed:
The study did not aim to use the originally de- • 
scribed and subsequently approved dose of h d i  
used in the e c o g  trials 4. A 25% dose reduction 
during the intravenous induction phase and a 
50% dose reduction during the subcutaneous 
maintenance phase leads to a consideration that 
only “modified h d i ” was tested by the Hellenic 
Cooperative Oncology Group.
The statistical design of the Greek trial is inap- • 
propriate for a modern clinical trial. None of the 
previous clinical trials conducted with conventional 
interferons or pegylated interferon alfa 2b—nor 
the meta-analysis by Wheatley et al.—showed 
more than a 10% difference in d f s  for one treatment 
arm as compared with another treatment arm or 
observation alone. Notably, most recent interferon 
alfa trials have compared one or two different 
interferon schemes with untreated controls. Be-
cause interferon has limited but clear activity in 
melanoma, expectation of a demonstration of a 
statistically significant difference between two 
interferon schedules appears to be very optimistic. 
It is much easier to show differences if interferon 
is compared with no treatment. The probability 
that 12 months of modified h d i  is 15% better than 
4 weeks of modified h d i  is extremely low. In the 
trial that led to the approval of h d i  for adjuvant 
treatment of melanoma, the absolute difference 
between h d i  and observation alone was only 7%!
The Greek trial was therefore clearly too underpow-
ered to detect small differences in efficacy between 
the two arms. In their article, Pectasides et al. spent 
more than half the discussion on a justification of 
their “non-inferiority study design.” They concluded 
that, according to the non-inferiority margin defined 
at study design, it can be ruled out that the 3-year 
relapse rate in arm A (1 month of treatment only) 
is higher by 15% or more than the relapse rate in 
arm B.
The authors correctly emphasize that “this study 
does not rule out the possibility of smaller differences 
between groups A and B.” They are referring to the ongo-
ing e c o g  1697 study comparing adjuvant h d i  for 1 month 
with observation alone, which “will give us more insight 
on the efficacy of this regimen in the adjuvant setting.” 
Whether this outlook on the e c o g  1697 trial is a fair one 
can be discussed, given that the e c o g  study is being per-
formed in a different setting, mainly with patients who 
are sentinel node–negative and with only a few whose 
lymph nodes not clinically palpable. Furthermore, the 
e c o g  1697 study uses the approved induction-phase dose 
of interferon alfa 2b (20×106 IU daily). The e c o g  study 
will, in principle, be able to respond to the question of 
whether the use of a high-dose induction phase at all is 
superior to a “wait and see” policy.
Is It Time to Switch from Conventional HDI to the 
Greek 4-Week Modified HDI Induction Treatment?
The Greek trial was truly underpowered: minor 
(<15%) but clinically meaningful differences in ef-
ficacy are not detectable. The regimen used was an 
unconventional and unapproved interferon alfa 2b 
scheme. On the other hand, a modified 4-week scheme 
seems to be attractive because of lesser toxicity and 
less time and fewer dollars consumed. This scheme 
could be considered for patients who are not willing to 
tolerate a classical 1-year h d i  or who are not eligible 
for h d i  for other reasons. In any case, the results of the HAUSCHILD
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complex Greek study need to be explained to patients, 
together with the various pros and cons.
Because the planning, conduct, and follow-up of 
a melanoma trial require approximately 10 years, it is 
very unlikely that this regimen will be tested again in 
another trial. Thus, we need to live with some open 
questions concerning the Greek trial.
What Are the Future Perspectives?
Large clinical trials on 1000 or more intermedi-
ate- and high-risk melanoma patients are currently 
under evaluation or approaching initiation. The e c o g  
1697 trial on a 4-week h d i  schedule has already been 
mentioned. A recently activated e o r t c  trial sponsored 
by Bristol–Myers Squibb on adjuvant ipilimumab 
compared with an intravenous placebo is under way, 
but that trial will certainly need a couple of years 
before final results are published. A large e o r t c  
trial sponsored by GlaxoSmithKline on a m a g e -a3 
(melanoma antigen family A, 3) vaccination will 
also be initiated in the second quarter of 2009. That 
trial is a good example of a newly developed targeted 
therapy, because only patients with m a g e -a3-positive 
melanoma will be considered.
A huge package of translational research objec-
tives is attached to all the newly designed clinical 
trials in the adjuvant setting. Hopefully, melanoma 
treatment will soon be able to be individualized on 
the basis of new predictive tumour-tissue or blood 
biomarkers. Without such biomarkers, there is only a 
little hope that more than a small subset of melanoma 
patients will reap benefit from adjuvant treatment. 
Let us cross our fingers that gene expression profil-
ing, together with sophisticated new techniques, is 
leading to more effective treatment modalities for 
melanoma patients.
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